You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Low-Cost Diagnostic Platform for Rapid Biochemical Detection

    SBC: TRITON SYSTEMS, INC.            Topic: DHA17B004

    Triton Systems will develop a novel approach to field-based disease and biochemical diagnostics through innovative use of extremely low cost bioanalytical devices.The proposed platform will provide a low cost, portable, and reliable diagnostic test for on-site use in austere and resource-limited environments.The devices will be highly durable, rugged, and easy to use without user-induced variation ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  3. Liver Surface Nodularity Score as a New Noninvasive Biomarker for Chronic Viral Hepatitis

    SBC: ImageIQ, Inc.            Topic: 300

    DESCRIPTION provided by applicant Chronic viral hepatitis is clinically silent until development of cirrhosis and hepatic decompensation Decompensated cirrhosis is a precursor to liver failure and is associated with increased risk of severe esophageal bleeding significant cardiovascular events and death The gold standard for diagnosing cirrhosis is liver biopsy though problems with the pro ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Live-Cell Fluorescence Lifetime FRET Assays for HTS

    SBC: Fluorescence Innovations, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain

    SBC: On Target Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases

    SBC: MAKSCIENTIFIC            Topic: 400

    RESEARCH andampRELATEDUnitPROJECT SUMMARY ABSTRACT In response to PAthe aim of this Phase I STTR proposal is to optimize and develop peripherally actingcannabinoidreceptorCB Rneutral antagonists displaying favorable therapeutic profiles for treating diabetic nephropathyDNDN is a chronic diabetic kidney disease and affectstypeand typediabetic patientsIt is characterized by persistent albuminuria an ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis

    SBC: KAPS BIOTECHNOLOGY LLC            Topic: 102

    Abstract Prostate cancerCaPis the most common non skin cancer in men and third most common cause of cancer deaths in menBlack men experience a higher burden of incidence and mortality from CaP compared to White menThe Prostate Specific AntigenPSAtesta commonly used biomarker for early diagnosis and management of CaPcannot alone accurately predict the presence of CaPits aggressivenessor the risk of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Jamboxx: Interactive Respiratory Therapy through Music and Gaming

    SBC: My Music Machines Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant The goal of this project is to develop a novel device for respiratory therapy that uses interactive gaming and music to encourage patient compliance In order to maintain pulmonary health many post operative surgery patients as well as people with quadriplegia and other spinal cord injuries high level motor neuron diseases such as amyotrophic lateral sclerosi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government